CYP17A1 and prostate carcinoma: In addition to CYP17A1, another key rate-limiting androgen biosynthesis enzyme, 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1, has emerged as a potential driver for therapeutic resistance in prostate cancer (1).